Asieris(SH:688176) Ge Long Hui A P P·2026-01-22 08:31Core Viewpoint - Asieris Pharmaceuticals has received ethical approval for its product APL-2401 to conduct Phase I clinical trials in Australia for patients with advanced solid tumors driven by FGFR2/3 [1] Group 1: Clinical Trial Approval - The company’s subsidiary, Asieris Pharmaceuticals (Aus) Pty Ltd, has obtained ethical approval from the Human Research Ethics Committee in Australia for APL-2401 [1] - The clinical trial has also been registered with the Therapeutic Goods Administration, the Australian drug regulatory authority [1] - APL-2401 has previously received approval from the National Medical Products Administration in China, indicating the company's commitment to advancing international multi-center clinical research [1] Group 2: Product Overview - APL-2401 is a highly selective small molecule inhibitor targeting FGFR2/3, developed to provide new treatment options for patients with advanced solid tumors such as urothelial carcinoma, cholangiocarcinoma, endometrial cancer, gastric cancer, breast cancer, ovarian cancer, non-small cell lung cancer, and other specific solid tumors [1] - The drug was optimized through the TAIDD platform, focusing on its selective mechanism for compound discovery and design [2] - APL-2401 demonstrates superior dual kinase inhibition activity compared to existing FGFR2 or FGFR3 selective inhibitors, with enhanced tumor cell killing and tumor microenvironment modulation effects [2] Group 3: Safety and Efficacy - Preclinical studies indicate that APL-2401 shows excellent efficacy and a wider safety window across various FGFR2/3 gene mutation, amplification, or overexpression models [2] - Compared to pan-FGFR inhibitors, APL-2401 significantly reduces the side effects associated with FGFR1 and FGFR4 [2] - The product exhibits potential best-in-class advantages in terms of activity, selectivity, safety, and druggability within the FGFR2/3 targeted therapy field [2]